Abstract PS5-08-21: Prospective breast cancer clinical validation study of an ultrasensitive, tumor-informed, whole genome, circulating tumor DNA assay to detect molecular residual disease and predict recurrence of high-risk early breast cancer treated with standard (neo)adjuvant therapy; NSABP B-64/EXActDNA/003/NCT06401421
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: M. Basik, E. Diego, G. Tang, S. Puhalla, M. Balic, M. Mandadi, J. Foldi, S. Seaward, M. George, A. Shipstone, S. Vemulapalli, J. Jones, W. J. Irvin, R. L. Mahtani, V. Valero, J. Frederick, B. Arrick, G. Young, J. A. Grigorieva, M. R. Palomares, F. Baehner, P. Rastogi, E. P. Mamounas, N. Wolmark, C. E. Geyer
Institutions: Jewish General Hospital, University of Pittsburgh, NRG Oncology, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NSABP Foundation, Baptist Health Louisville, Kaiser Permanente, Kaiser Permanente Vallejo Medical Center, Rutgers Cancer Institute, Ballad Health, Aultman Health Foundation, Avera Health, Bon Secours Mercy Health, Baptist Hospital of Miami, Baptist Health South Florida, The University of Texas MD Anderson Cancer Center, Exact Sciences (United States), AdventHealth Orlando
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129584685
Cites:
Cited by:
Related to: